Telma ACT 40/5/6.25 mg Tablet

• Treats high blood pressure (Hypertension)
  

Telma ACT 40/5/6.25mg tablet cause several side effects that are easily manageable with certain treatment options. If any of the following symptoms persist or worsen consult the healthcare professional instantly:

• Fatigue (tiredness)
• Bradycardia
• Gastrointestinal disturbance
• Electrolyte imbalance
• The increased glucose level in the blood
• Postural hypotension
• Angioedema and urticaria
• Visual disturbance
• Breathlessness
• Muscle cramp
• Headache
• Dizziness
• Sleepiness
• Ankle swelling​

• Doctor prescription is required while using Telma ACT 40/5/6.25mg tablet to ensure safe and effective treatment option.
• The tablet should be taken with or without food at the same time every day to enhance the effectiveness, maintain consistent blood pressure and reduce the risk of side effects.
• Do not crush, chew or break the tablet as it decrease the effectiveness of the medication and alter its absorption.​
  

• Telma ACT 40/5/6.25mg tablet contains three drugs that lowers blood pressure by Angiotensin-II (constricts vessels), inhibiting calcium entry into muscles (relaxes vessels), and reducing excess fluid/sodium. Telmisartan(40mg) acts as an angiotensin II receptor blocker (ARB) which preventing vasoconstriction and narrowing of blood vessels.
• Amlodipine (5mg) is a calcium channel blocker that prevents calcium from entering vascular smooth muscle cells, causing blood vessels to relax and widen. Chlorthalidone (6.25mg) is a thiazide like diuretic that reducing fluid volume and improving blood flow.​​
  

• McClellan, K. J., & Markham, A. (1998). Telmisartan. Drugs, 56(6). https://pubmed.ncbi.nlm.nih.gov/9878991/
• Sharpe, M., Jarvis, B., & Goa, K. L. (2001). Telmisartan: a review of its use in hypertension. Drugs, 61(10), 1501-1529. https://pubmed.ncbi.nlm.nih.gov/11558835/
• Wang, J. G., Palmer, B. F., Vogel Anderson, K., & Sever, P. (2023). Amlodipine in the current management of hypertension. The Journal of Clinical Hypertension, 25(9), 801-807. https://pubmed.ncbi.nlm.nih.gov/37551050/
• Şen, S., Demir, M., Yiğit, Z., & Üresin, A. Y. (2018). Efficacy and safety of s-amlodipine 2.5 and 5 mg/d in hypertensive patients who were treatment-naive or previously received antihypertensive monotherapy. Journal of Cardiovascular Pharmacology and Therapeutics, 23(4), 318-328. https://pubmed.ncbi.nlm.nih.gov/29649885/
• RAGHAVENDRA, R., Kota, R. K., Setty, C. M., & PURUSHOTHAM, R. (2009). Formulation and evaluation of fast dissolving chlorthalidone tablets. International journal of pharmacy and pharmaceutical sciences, 1(1), 79-87. https://www.researchgate.net/publication/288455994_Formulation_and_evaluation_of_fast_dissolving_chlorthalidone_tablets​